News & Updates

Uric acid not linked to major depressive disorder

15 Dec 2022

There appears to be no significant association between serum uric acid (SUA) and major depressive disorder (MDD), suggest the results of a meta-analysis and two-sample bidirectional Mendelian randomization (MR) study.

Uric acid not linked to major depressive disorder

15 Dec 2022

ALXN1840 generates rapid, sustained copper mobilization in Wilson disease

15 Dec 2022 by

In individuals with Wilson disease (WD), a rare disease of copper metabolism, ALXN1840 led to significantly greater copper mobilization compared with standard of care (SoC), findings from a rater-blinded phase III study have shown.

ALXN1840 generates rapid, sustained copper mobilization in Wilson disease

15 Dec 2022

Upadacitinib rapidly effective in ulcerative colitis

15 Dec 2022

Treatment with upadacitinib appears to produce improvements in ulcerative colitis (UC) symptoms as early as day 1, as shown in a recent study.

Upadacitinib rapidly effective in ulcerative colitis

15 Dec 2022

Maralixibat improves pruritus across all PFIC types

14 Dec 2022 by

Treatment with maralixibat significantly reduced the severity of pruritus in children with progressive familial intrahepatic cholestasis (PFIC) in the MARCH-PFIC* study presented at The Liver Meeting 2022.

Maralixibat improves pruritus across all PFIC types

14 Dec 2022

Odevixibat improves pruritus, reduces bile acids in children with ALGS

13 Dec 2022 by

Treatment with odevixibat, a potent, selective IBAT* inhibitor, significantly improved pruritus and reduced serum bile acid levels in children with Alagille syndrome (ALGS), according to the ASSERT** trial presented at The Liver Meeting 2022.

Odevixibat improves pruritus, reduces bile acids in children with ALGS

13 Dec 2022

Durvalumab plus gemcitabine-cisplatin improves survival in advanced BTC

12 Dec 2022 by

First-line treatment with durvalumab plus gemcitabine and cisplatin (GC) leads to improved overall (OS) and progression-free survival (PFS) in advanced biliary tract cancer (BTC) across genomic variants, according to the results of the phase III study TOPAZ-1, presented at the ESMO Asia 2022.

Durvalumab plus gemcitabine-cisplatin improves survival in advanced BTC

12 Dec 2022

Resmetirom safe, effective in improving NASH fibrosis markers

12 Dec 2022 by

Treatment with the selective THR-β* agonist resmetirom for 52 weeks was well-tolerated and effective in reducing markers of NASH** fibrosis in a well-compensated Child-Pugh (CP)-A NASH population, a phase III trial has shown.

Resmetirom safe, effective in improving NASH fibrosis markers

12 Dec 2022

Which dietary interventions benefit IBD patients?

12 Dec 2022

In dietary trials for inflammatory bowel disease (IBD), there appears to be some evidence of a benefit with partial enteral nutrition for induction and maintenance of remission in Crohn’s disease (CD), according to a study. However, lowering intake of red meat and refined carbohydrates does not exert any effect in terms of reducing the risk of CD relapse.